Interaction of poly(styrene sulfonic acid) with the alternative pathway of the serum complement system

被引:7
作者
Murakami, Y
Iwata, H
Kitano, E
Kitamura, H
Ikada, Y
机构
[1] Kyoto Univ, Inst Frontier Med Sch, Sakyo Ku, Kyoto 6068507, Japan
[2] Osaka Prefuctural Coll Hlth Sci, Osaka 5838555, Japan
[3] Suzuka Univ Med Sci, Suzuka, Mie 5100293, Japan
基金
日本学术振兴会;
关键词
poly(styrene sulfonic acid); polyanion; alternative pathway of the complement system; immunoisolation membrane; in vitro;
D O I
10.1163/1568562053654095
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Bioartificial pancreas, in which the islets of Langerhans are enclosed in artificial membrane to be protected from the host immune system, is expected to be a promising medical device to treat patients who suffer from insulin-dependent diabetes. Our strategy for preparation of a bioartificial pancreas involves utilizing a membrane including polymeric materials that can inhibit the complement reaction. In this study, we examined the effects of poly(styrene sulfonic acid) (PSSa) on the alternative pathway of the serum complement system to identify the mechanism(s) involved. PSSa was dissolved in pooled normal human serum (NHS), and the mixtures were incubated at 37 degrees C for 30 min. Complement activities in sera were determined by hemolytic assays. Amounts of complement activation products released were determined by ELISA. Interactions of PSSa with complement components and fragments were examined with electrophoresis and immunoblotting. From these examinations, it appeared that the manner of PSSa effects on the alternative pathway (AP) highly depends on its concentration. PSSa seemingly acted as an activator when its concentration was 0.005 g/dl to 0.05 g/dl, while it acted as an inhibitor when its concentration was more than 0.1 g/dl. In terms of activation or inhibition of the AP, forming complex of PSSa with factor H induced activation, and that with factor D induced inhibition.
引用
收藏
页码:381 / 395
页数:15
相关论文
共 36 条
[31]   COVALENT ASSOCIATION OF C3B WITH C4B WITHIN C5 CONVERTASE OF THE CLASSICAL COMPLEMENT PATHWAY [J].
TAKATA, Y ;
KINOSHITA, T ;
KOZONO, H ;
TAKEDA, J ;
TANAKA, E ;
HONG, K ;
INOUE, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 165 (06) :1494-1507
[32]   Interaction of fucoidan with the proteins of the complement classical pathway [J].
Tissot, B ;
Montdargent, B ;
Chevolot, L ;
Varenne, A ;
Descroix, S ;
Gareil, P ;
Daniel, R .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2003, 1651 (1-2) :5-16
[33]   ELECTROPHORETIC TRANSFER OF PROTEINS FROM POLYACRYLAMIDE GELS TO NITROCELLULOSE SHEETS - PROCEDURE AND SOME APPLICATIONS [J].
TOWBIN, H ;
STAEHELIN, T ;
GORDON, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (09) :4350-4354
[34]   SEPARATION OF 9 COMPONENTS AND 2 INACTIVATORS OF COMPONENTS OF COMPLEMENT IN HUMAN SERUM [J].
VROON, DH ;
SCHULTZ, DR ;
ZARCO, RM .
IMMUNOCHEMISTRY, 1970, 7 (01) :43-&
[35]   MODULATION OF FORMATION OF AMPLIFICATION CONVERTASE OF COMPLEMENT, C3B,BB, BY NATIVE AND COMMERCIAL HEPARIN [J].
WEILER, JM ;
YURT, RW ;
FEARON, DT ;
AUSTEN, KF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1978, 147 (02) :409-421
[36]   Ethnicity/race, paranoia, and psychiatric diagnoses: Clinician bias versus sociocultural differences [J].
Whaley, AL .
JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT, 1997, 19 (01) :1-20